Skip to main content
    C

    CVRx Inc (CVRX)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $0.61
    +0.01 (+0.92%)

    Market Cap: $17.30M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    CVRx Inc (CVRX) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    CVRX is expected to report earnings on Feb 10, 2027. In the quarter ended Sep 30, 2026, CVRX reported EPS of -$0.52, below the -$0.49 estimate. It beat the EPS estimate in 2 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    39%(9/23)
    Avg Surprise
    -8.85%

    Upcoming Estimates

    Reports Feb 10, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.52
    Range-$0.53 - -$0.51
    9 analysts
    Revenue Consensus
    $12.79M
    Range$11.47M - $15.22M
    9 analysts
    Reports May 10, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.49
    Range-$0.57 - -$0.44
    5 analysts
    EPS Revisions
    2
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.50+1.5%
    60d ago-$0.50+1.5%
    30d ago-$0.50+1.5%
    7d ago-$0.50+1.5%
    Current-$0.49
    Revenue Consensus
    $13.73M
    Range$11.50M - $14.93M
    5 analysts

    Next Report

    CVRX has an expected report date of Feb 10, 2027.

    CVRX Earnings Call

    The latest CVRX earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 23 quarters below that had an estimate, CVRX beat 9, missed 11 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $13.83M, down 5.9% from $14.69M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.52-$0.49-$0.53 - -$0.47-6.12%MissN/A53 up, 2 downNov 5, 2026$13.83M
    Jun 30, 2026-$0.53-$0.52-$0.57 - -$0.46-1.92%MissN/A74 up, 1 downAug 6, 2026$15.71M
    Mar 31, 2026-$0.50-$0.50-$0.56 - -$0.450.00%In lineN/A72 up, 0 downMay 11, 2026$14.77M
    Dec 31, 2025-$0.46-$0.44-$0.48 - -$0.42-4.55%MissN/A72 up, 0 downFeb 12, 2026$16.02M
    Sep 30, 2025-$0.49-$0.50-$0.53 - -$0.47+2.00%BeatN/A72 up, 4 downNov 5, 2025$14.69M
    Jun 30, 2025-$0.57-$0.52-$0.58 - -$0.45-9.62%MissN/A73 up, 0 downAug 4, 2025$13.59M
    Mar 31, 2025-$0.53-$0.57-$0.71 - -$0.37+7.02%BeatN/A70 up, 4 downMay 8, 2025$12.35M
    Dec 31, 2024-$0.43-$0.38-$0.42 - -$0.34-13.16%MissN/A73 up, 0 downFeb 4, 2025$15.34M
    Sep 30, 2024-$0.57-$0.47-$0.51 - -$0.42-21.28%MissN/A70 up, 0 downOct 29, 2024$13.37M
    Jun 30, 2024-$0.65-$0.55-$0.63 - -$0.35-18.18%MissN/A60 up, 0 downJul 29, 2024$11.81M
    Mar 31, 2024-$1.04-$0.54-$0.60 - -$0.49-92.59%MissN/A60 up, 0 downApr 30, 2024$10.77M
    Dec 31, 2023-$0.44-$0.55-$0.57 - -$0.49+20.00%BeatN/A62 up, 0 downJan 25, 2024$11.30M
    Sep 30, 2023-$0.43-$0.58-$0.61 - -$0.54+25.86%BeatN/A60 up, 0 downOct 26, 2023$10.51M
    Jun 30, 2023-$0.56-$0.58-$0.63 - -$0.54+3.45%BeatN/A60 up, 0 downJul 25, 2023$9.50M
    Mar 31, 2023-$0.55-$0.57-$0.61 - -$0.50+3.51%BeatN/A60 up, 0 downApr 27, 2023$7.98M
    Dec 31, 2022-$0.51-$0.56-$0.59 - -$0.53+8.93%BeatN/A50 up, 0 downJan 26, 2023$7.18M
    Sep 30, 2022-$0.48-$0.56-$0.59 - -$0.53+14.29%BeatN/A50 up, 0 downNov 1, 2022$6.19M
    Jun 30, 2022-$0.54-$0.53-$0.57 - -$0.51-1.89%MissN/A50 up, 0 downJul 28, 2022$5.03M
    Mar 31, 2022-$0.49-$0.49-$0.50 - -$0.460.00%In lineN/A40 up, 0 downApr 25, 2022$4.08M
    Dec 31, 2021-$0.52-$0.44-$0.47 - -$0.43-18.18%MissN/A40 up, 0 downFeb 15, 2022$3.66M
    Sep 30, 2021-$0.30-$0.40-$0.41 - -$0.34+25.00%BeatN/A4N/ANov 4, 2021$3.40M
    Jun 30, 2021-$48.48-$21.45-$48.48 - -$0.64-126.01%MissN/A4N/AAug 4, 2021$3.12M
    Mar 31, 2021-$0.70-$0.70N/A0.00%In lineN/AN/AN/AJun 2, 2021$2.86M
    Dec 31, 2020-$0.60N/AN/AN/AN/AN/AN/AN/AMar 31, 2021$2.09M
    Dec 31, 2019-$0.21N/AN/AN/AN/AN/AN/AN/AMar 30, 2020N/A
    Last 25 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$2.05, after -$2.69 the year before. It was -$0.21 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$2.05N/A
    Dec 31, 2024-$2.69N/A
    Dec 31, 2023-$1.98N/A
    Dec 31, 2022-$2.02N/A
    Dec 31, 2021-$50.00N/A
    Dec 31, 2020-$0.60N/A
    Dec 31, 2019-$0.21N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,400 words across 7 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20265,3577
    2026Q2Jun 30, 20264,5337
    2026Q1Mar 31, 20265,00110
    2025Q4Dec 31, 20255,89210
    2025Q3Sep 30, 20255,31911
    2025Q2Jun 30, 20255,97811
    2025Q1Mar 31, 20255,8027
    2024Q4Dec 31, 20245,42210

    2026Q3 Earnings Call

    Opening remarks

    Michael Vallie ICR Healthcare Representative and Call Moderator Good afternoon. Thank you for joining us today for CVRx's Third Quarter 2026 Earnings Conference Call. Joining me on today's call are the company's President and Chief Executive Officer, Kevin Hykes, and Jared Oasheim, our Chief Financial Officer, who will review our financial results. We are also pleased to have with us John Landry, the company's incoming Chief Financial Officer, who joined in October and will assume the CFO role following the filing of our Form 10-Q. The remarks today will contain forward-looking statements, including statements about financial guidance. These statements are based on plans and expectations as of today, which may change over time. In addition, actual results could differ materially due to a number of risks and uncertainties, including those identified in the earnings release issued prior to this call and in the company's SEC filings. I would now like to turn the call over to CVRx's President and Chief Executive Officer, Kevin Hykes.

    Kevin Hykes President and Chief Executive Officer Thanks, Mark. Good afternoon, and thank you for joining our third quarter 2026 earnings call. We delivered total revenue of $13.8 million in the third quarter, within our guidance range, with a steady gross margin of 87%. Revenue declined 6.1% from the same quarter last year, with U.S. revenue down 4% and Europe down 27%. We continued to stabilize our U.S. sales organization, and a second major payer added a Barostim coverage policy for its Medicare Advantage enrollees. However, the headwinds we have been working through are more impactful and more persistent than we anticipated. While tenure is improving, the impact on performance is taking longer to materialize than we had expected. In part due to these headwinds, I want to give you a fuller picture of what is shaping our business. I will cover three areas: the three headwinds we are facing, which are reimbursement, physician champion turnover, and field execution, and what we are doing about each; what is working in our most stable regions and how we are extending it; and the clinical evidence that is building behind Barostim. I will then introduce our incoming Chief Financial Officer, John Landry, before Jared reviews our financial results. The first headwind is reimbursement. Specifically, the change in behavior from our largest Medicare Advantage payer, which further degraded over the course of the third quarter. Our reimbursement visibility is limited to prior authorizations that we are involved with, which likely represents less than half of all prior authorizations. For those that we handle directly, the approvals that previously occurred within days are now taking three months or longer.

    Frequently Asked Questions About CVRX

    When is CVRX's next earnings date?

    CVRX's next earnings report is expected for Feb 10, 2027.

    Did CVRX beat earnings estimates last quarter?

    No. CVRX reported EPS of -$0.52 for the quarter ended Sep 30, 2026, below the -$0.49 estimate by 6.12%.

    What EPS do analysts expect from CVRX next quarter?

    The consensus EPS estimate for CVRX for the quarter ending Dec 31, 2026 is -$0.52 from 9 analysts, with estimates from -$0.53 to -$0.51.

    How often does CVRX beat earnings estimates?

    CVRX beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -3.29%.